Comparative Pharmacology
Head-to-head clinical analysis: TASMAR versus TOLCAPONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TASMAR versus TOLCAPONE.
TASMAR vs TOLCAPONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which increases the bioavailability of levodopa by reducing its peripheral metabolism.
Tolcapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). It inhibits both peripheral and central COMT activity, thereby reducing the metabolism of levodopa to 3-O-methyldopa and increasing the bioavailability and duration of action of levodopa in the brain.
100 mg orally three times daily; maximum 200 mg three times daily.
100 mg orally three times daily. The first dose of the day should be taken together with the first daily dose of levodopa/carbidopa.
None Documented
None Documented
Clinical Note
moderateTolcapone + Torasemide
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Torasemide."
Clinical Note
moderateTolcapone + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Etacrynic acid."
Clinical Note
moderateTolcapone + Furosemide
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Furosemide."
Clinical Note
moderateTolcapone + Bumetanide
Terminal elimination half-life is 2–3 hours in healthy volunteers; clinically, this short half-life necessitates three-times-daily dosing to maintain COMT inhibition, though peripheral COMT activity recovers within 4–6 hours.
Terminal elimination half-life is 2–3 hours in healthy subjects; in patients with hepatic impairment, it may be prolonged up to 8–10 hours, necessitating dose reduction.
Primarily hepatic metabolism (glucuronidation and methylation), with approximately 40% of the dose excreted in urine as metabolites and <0.5% as unchanged drug; about 50% is eliminated in feces via biliary excretion.
Primarily hepatic metabolism (glucuronidation and methylation), with minimal renal excretion of unchanged drug. Fecal excretion accounts for approximately 40% of the dose, with 14% excreted in urine as glucuronide conjugates. Less than 1% of the dose is recovered as unchanged tolcapone in urine.
Category C
Category A/B
COMT Inhibitor
COMT Inhibitor
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Bumetanide."